Bone morphogenetic protein use in spine surgery in the United States: how have we responded to the warnings?
- 1 September 2017
- journal article
- Published by Elsevier in The Spine Journal
- Vol. 17 (9) , 1247-1254
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Biologics in Spine ArthrodesisJournal of Spinal Disorders & Techniques, 2015
- Use of bone morphogenetic protein among patients undergoing fusion for degenerative diagnoses in the United States, 2002 to 2012The Spine Journal, 2015
- Trends in Bone Morphogenetic Protein Usage since the U.S. Food and Drug Administration Advisory in 2008: What Happens to Physician Practices When the Food and Drug Administration Issues an Advisory?Global Spine Journal, 2013
- Cancer Risk After Use of Recombinant Bone Morphogenetic Protein-2 for Spinal ArthrodesisJournal of Bone and Joint Surgery, 2013
- A critical review of recombinant human bone morphogenetic protein-2 trials in spinal surgery: emerging safety concerns and lessons learnedThe Spine Journal, 2011
- Complications of anterior cervical discectomy and fusion using recombinant human bone morphogenetic protein-2European Spine Journal, 2007
- Increased Swelling Complications Associated With Off-Label Usage of rhBMP-2 in the Anterior Cervical SpineSpine, 2006
- Bone morphogenetic proteins (BMPs): how do they function and what can they offer the clinician?Journal of Oral Science, 2003
- Use of Recombinant Human Bone Morphogenetic Protein-2 to Achieve Posterolateral Lumbar Spine Fusion in HumansSpine, 2002
- Natural History of Posterior Iliac Crest Bone Graft Donation for Spinal SurgerySpine, 2001